for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Takeda Pharmaceutical Co Ltd

4502.T

Latest Trade

3,758.00JPY

Change

-22.00(-0.58%)

Volume

7,116,200

Today's Range

3,724.00

 - 

3,793.00

52 Week Range

2,894.50

 - 

4,216.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Takeda Secures Global Rights From Ovid Therapeutics To Develop, Commercialize Soticlestat

March 3 (Reuters) - Ovid Therapeutics::OVID THERAPEUTICS - TAKEDA SECURES GLOBAL RIGHTS FROM CO TO DEVELOP, COMMERCIALIZE SOTICLESTAT TO TREAT DRAVET SYNDROME, LENNOX-GASTAUT SYNDROME.OVID THERAPEUTICS - CO IS ELIGIBLE TO GET UPTO $856 MILLION IN PAYMENTS, INCLUDING UPFRONT PAYMENT OF $196 MILLION.OVID - ELIGIBLE TO GET UPTO $660 MILLION UPON ACHIEVING MILESTONES, TIERED ROYALTIES FROM LOW DOUBLE-DIGITS & UPTO 20% ON SALES OF SOTICLESTAT.OVID THERAPEUTICS - TAKEDA PLANS TO INITIATE PHASE 3 STUDIES IN CHILDREN, ADULTS WITH DRAVET SYNDROME & LENNOX-GASTAUT SYNDROME IN CALENDAR YEAR Q2 2021.OVID THERAPEUTICS - ORIGINAL 2017 COLLABORATION BETWEEN CO & TAKEDA TO CONCLUDE; CO WILL HAVE NO FURTHER DEVELOPMENT OR MILESTONE OBLIGATIONS.

Novavax And Takeda Finalize License Agreement For Novavax’ Covid-19 Vaccine Candidate In Japan

Feb 26 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX AND TAKEDA FINALIZE LICENSE AGREEMENT FOR NOVAVAX’ COVID-19 VACCINE CANDIDATE IN JAPAN; TAKEDA INITIATES PHASE 1/2 TRIAL IN JAPAN.NOVAVAX INC - AGREEMENT INCLUDES COVID-19 VACCINE TECHNOLOGY TRANSFER TO TAKEDA FOR LOCAL MANUFACTURING AND COMMERCIALIZATION IN JAPAN.NOVAVAX INC - TAKEDA DOSES FIRST PARTICIPANT IN IMMUNOGENICITY AND SAFETY STUDY TO SUPPORT LOCAL REGULATORY APPLICATION.NOVAVAX INC - NOVAVAX WILL BE ENTITLED TO RECEIVE PAYMENTS BASED ON ACHIEVEMENT OF CERTAIN DEVELOPMENT AND COMMERCIAL MILESTONES.NOVAVAX INC - TAKEDA ANTICIPATES CAPACITY TO MANUFACTURE OVER 250 MILLION DOSES OF COVID-19 VACCINE PER YEAR.NOVAVAX INC - TAKEDA ANTICIPATES CAPACITY TO MANUFACTURE OVER 250 MILLION DOSES OF COVID-19 VACCINE PER YEAR.NOVAVAX INC - NOVAVAX WILL BE ENTITLED TO RECEIVE A PORTION OF PROCEEDS FROM VACCINE..NOVAVAX INC - TAKEDA IS RESPONSIBLE FOR REGULATORY SUBMISSION TO JAPAN'S PMDA AND WILL MANUFACTURE AND COMMERCIALIZE NVX-COV2373 IN JAPAN.

Takeda’s Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy

Feb 12 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA’S MARIBAVIR PHASE 3 CLINICAL TRIAL MET PRIMARY ENDPOINT OF SUPERIORITY TO CONVENTIONAL ANTIVIRAL THERAPY IN TRANSPLANT RECIPIENTS WITH REFRACTORY, WITH OR WITHOUT RESISTANCE, CYTOMEGALOVIRUS INFECTION/DISEASE.TAKEDA PHARMACEUTICAL CO LTD - PHASE 3 CLINICAL TRIAL ALSO DEMONSTRATED FEWER TREATMENT-LIMITING ADVERSE EVENTS.TAKEDA PHARMACEUTICAL CO LTD - TWO TREATMENT-RELATED SERIOUS TEAES LED TO DEATH.

KSQ Therapeutics- Co And Takeda Enter Broad Strategic Collaboration To Research, Develop And Commercialize Novel Immuno-Oncology Therapies

Jan 13 (Reuters) - KSQ Therapeutics::KSQ THERAPEUTICS- CO AND TAKEDA ENTER BROAD STRATEGIC COLLABORATION TO RESEARCH, DEVELOP AND COMMERCIALIZE NOVEL IMMUNO-ONCOLOGY THERAPIES.KSQ THERAPEUTICS - COLLABORATION INCLUDES TWO T-CELL PROGRAMS AND AN EXPANSIVE DISCOVERY PROGRAM TO IDENTIFY NATURAL KILLER (NK) CELL TARGETS.KSQ THERAPEUTICS - POTENTIAL FOR MORE THAN $100 MILLION IN UPFRONT AND PRECLINICAL MILESTONE PAYMENTS.KSQ THERAPEUTICS - RETAINS U.S. COST/PROFIT-SHARING OPTION ON ONE PRODUCT, AND IS ENTITLED TO POTENTIAL ROYALTIES FOR EACH COMMERCIALIZED PRODUCT.

Takeda Provides Pipeline Update And Shares Goal To Increase Revenue 50% By Fy2030 At The 39Th Annual J.P. Morgan Healthcare Conference

Jan 11 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA PROVIDES PIPELINE UPDATE AND SHARES GOAL TO INCREASE REVENUE 50% BY FY2030 AT THE 39TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.TAKEDA PHARMACEUTICAL CO LTD - RAPID DELEVERAGING ON TRACK TO ACHIEVE TARGET OF 2X NET DEBT / ADJUSTED EBITDA WITHIN FISCAL YEARS 2021 TO 2023.TAKEDA PHARMA - PIPELINE PORTFOLIO HAS POTENTIAL TO CONTRIBUTE SIGNIFICANTLY TO REVENUE GROWTH, HAS GOAL TO REACH JPY5 TRILLION ($47 BILLION) REVENUE BY FY2030.TAKEDA PHARMACEUTICAL - ON TRACK TO ACHIEVE TARGETED ANNUAL RUN RATE OF $2.3 BILLION IN COST SYNERGIES BY END OF FY2021.

U.S. FDA Approves Supplemental New Drug Application For Takeda’S Iclusig (Ponatinib) For Adult Patients With Resistant Or Intolerant Chronic-Phase Cml

Dec 18 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::U.S. FDA APPROVES SUPPLEMENTAL NEW DRUG APPLICATION FOR TAKEDA’S ICLUSIG® (PONATINIB) FOR ADULT PATIENTS WITH RESISTANT OR INTOLERANT CHRONIC-PHASE CML.

Takeda Pharmaceutical - Making Nihon Pharmaceutical A Wholly Owned Subsidiary Through Simple Share Exchange

Nov 24 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::MAKING NIHON PHARMACEUTICAL CO., LTD. A WHOLLY OWNED SUBSIDIARY THROUGH SIMPLE SHARE EXCHANGE.

Moderna Says Partners With Takeda, Govt Of Japan To Supply 50 Mln Doses Of Co's COVID-19 Vaccine Candidate

Oct 29 (Reuters) - Moderna Inc <MRNA.O>::MODERNA PARTNERS WITH TAKEDA AND THE GOVERNMENT OF JAPAN TO SUPPLY 50 MILLION DOSES OF MRNA VACCINE AGAINST COVID-19 (MRNA-1273) TO JAPAN.MHLW AND TAKEDA WILL IMPORT AND DISTRIBUTE MRNA-1273 IN JAPAN STARTING IN FIRST HALF OF 2021.MODERNA-CO RESPONSIBLE FOR ALL IMPORT,LOCAL REGULATORY,DEVELOPMENT,DISTRIBUTION ACTIVITIES IN JAPAN TO ENSURE TIMELY ACCESS STARTING FIRST HALF OF 2021.

Kamada Sees FY 2020 Revenue $132 Million To $137 Million

Oct 7 (Reuters) - Kamada Ltd <KMDA.TA>::SEES FY 2020 REVENUE $132 MILLION TO $137 MILLION.EXPECTS TO RECEIVE $25 MILLION IN REVENUES FROM SALES OF GLASSIA TO TAKEDA IN 2021.PROJECTS ROYALTIES FROM TAKEDA IN RANGE OF $10 MILLION TO $20 MILLION PER YEAR FROM 2022 TO 2040.TAKEDA ANTICIPATES THAT ITS 2021 GLASSIA DEMAND FROM KAMADA WILL NOT EXCEED MINIMUM COMMITMENT UNDER SUPPLY AGREEMENT.FY2020 REVENUE VIEW $134.9 MILLION -- REFINITIV IBES DATA.

Elektrofi, Takeda Enter Agreement On Elektrofi's Formulation Tech

Sept 21 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::ELEKTROFI - CO & TAKEDA PHARMACEUTICAL ENTER INTO EVALUATION AGREEMENT ON ELEKTROFI'S FORMULATION TECHNOLOGY.ELEKTROFI - FINANCIAL TERMS OF AGREEMENT AND MILESTONES ARE NOT BEING DISCLOSED.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up